Get App Open
In App
Open App
you are here:

Biocon Ltd.

BSE: 532523 | NSE: BIOCON |

Represents Equity.Intra - day transactions are permissible and normal trading is done in this category
Series: EQ | ISIN: INE376G01013 | SECTOR: Pharmaceuticals

BSE Live

Dec 05, 16:01
279.05 -4.65 (-1.64%)
  • Prev. Close


  • Open Price


  • Bid Price (Qty.)

    279.05 (329)

  • Offer Price (Qty.)

    279.15 (31)

NSE Live

Dec 05, 15:59
279.45 -4.10 (-1.45%)
  • Prev. Close


  • Open Price


  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    279.45 (844)

Company History - Biocon
 -The Biocon India group promoter of Biocon India Ltd.  Ms Kiran
 Mazumdar Shaw, Chairman and Managing Director of Biocon India Group.
 -Biocon India appointed DSP Merrill Lynch and Kotak Mahindra for its
 Rs 150-crore IPO scheduled for June next year. Biocon-Shantha
 Biotech, the 50:50 joint venture between Biocon India and Shantha
 Biotechnics, focuses on the domestic and global human insulin markets
 by maximizing on R&D manufacturing and regulatory capacities of the
 two companies.
 -ICICI Venture offloads 10-pc stake in Biocon
 -Clinigene International inaugurates human pharmacology unit for
 clinical trials
 -Comes out with an Initial Public Offering (IPO) of 10 million shares
 at a price of Rs 315 per share for a face value of Rs 5 per share
 which constitutes 10% of the post-issue capital (Rs 100 crore),
 listed at Rs 425
 -Biocon Ltd has entered into a nine-year export contract with US
 major Bristol-Myers Squibb Co to supply the bulk form of its
 recombinant human insulin
 -Biocon forays into lifestyle drugs market
 -Biocon's clinical research arm, Clinigene International Pvt Ltd.
 re-accredited by the College of American Pathologists (CAP) following
 a recent inspection
 -Biocon Ltd has informed that in an unusual commercial transaction
 between Cuba and USA, a Californian Biotechnology Company, CancerVax
 Corporation received a rare US Government approval to License three
 experimental cancer drugs from a leading Cuban Institute (CIMAB)
 -Biocon said on July 26 that its Cuban partner CIMAB (Centre for
 Molecular Immunology) in the joint venture with Biocon
 Biopharmaceuticals will be able to license out three experimental
 cancer drugs to a Californian Biotechnology company, CancerVax
 -Biocon, Syngene enters into Research Agreement with Novartis
 Institutes for Biomedical Research Inc
 -Biocon unveils new bio insulin
 Biocon signs MoU with Karolinska Institute.
 -Ms Kiran Mazumdar-Shaw, CMD of Biocon Ltd, has been honoured with
 the Corporate Leadership Award 2005 of the American India Foundation
 -Biocon signs Licensing agreement with Bentley Pharmaceuticals Inc.
 -Biocon ties up with ICICI Prudential Life Insurance
 -Biocon concludes Phase-IV trials of Insugem
 -Biocon Ltd and Abu Dhabi based pharmaceutical company Neopharma have
 signed an MOU to establish a JV to manufacture and market a range of
 Bio-pharmaceuticals for the GCC countries (Gulf Cooperation
 -Biocon Ltd on March 14, 2007 has announced that its subsidiary
 Company Syngene has entered into a research partnership with
 Bristol-Myers Squibb.
 -Biocon signs MOU with Neopharma for a JV
 -The Company has issued Bonus Shares in the Ratio of 1:1.
 - Biocon and Amylin Pharmaceuitcals Inc have entered into an
 exclusive agreement to jointly develop, commercialise and manufacture
 a new peptide therapeutic for potential treatment of diabetes. The two
 companies will share development costs.
 -Biocon launches BASALOG - long lasting basal insulin for Type 1 &
 Type 2 Diabetics
 -Biocon joins hands with Amylin Pharmaceuticals
 -Biocon inks partnership with ISB to launch the Biocon Cell for
 Innovation Management
 - Biocon has launched its new 'comprehensive care' division,
 dedicated to provide affordable solutions to critical illnesses such
 as nosocomial infections, post surgical complications, trauma and
 medical emergencies.
 - Biocon has signed an agreement with Teleradiology Solutions to
 provide teleradiology reporting services to Clinigene, Biocon's
 clinical research arm.
 -Biocon announces preliminary data on its novel oral insulin drug
 -Biocon announces project commencement for first high-end
 biopharmaceutical manufacturing and R&D facility in Bio-XCell,
 -Biocon launches INSUPen, a convenient and affordable reusable
 insulin delivery device
 -Clinigene International Enters into Collaborative Clinical Research
 -Biocon wins Biospectrum BioPharma Company of the year award
 -Biocon wins Best Design and Information Award for the Healthcare
 Sector at Bangalore India Bio
 -Biocon wins Excellence in Environmental Management Award
 -Biocon wins Best Exhibitor Award in the category of Biocontent and
 Information at Bangalore India Bio
 -Biocon wins Golden Peacock National Quality Award 
 -Biocon Research Centre Inaugurated by Nobel Laureate Prof Kurt
 -Biocon announces that it has entered into an option agreement with
 Bristol-Myers Squibb for 
 Biocons IN-105, an oral insulin drug candidate
 -Biocon Launches ALZUMAb - a First in Class Novel Biologic Treatment
 for Psoriasis Patients in India.
 -Biocon Enhances Partnership with Mylan through Strategic
 Collaboration for Insulin Products.
 -Biocon Partners with CytoSorbents to Market CytoSorb-A
 First-in-Class Therapy for Sepsis Management.
 -Biocon Ranked at No. 6 among Top 20 Global Biotech Employers by the
 Science Magazine.
 -Biocon the Top Ten Most Admired Companies in the Pharma & Healthcare
 -Biocon wins Best Design and Innovation Exhibitor Award at Bangalore
 India Bio.
 -Biocon has been conferred with the Sir J C Bose Memorial Award 2013
 (Institutional category) by Indian Science Monitor (ISM) for its
 contribution in the field of Biotechnology, with special reference to
 the launch of ALZUMAb (Itolizumab).
 -Biocon Foundation gets 'Asia Best CSR Practices Award 2014 for
 ''Cervical Cancer Screening Programme''.
 -Biocon wins Thomson Reuters India Innovation Awards 2014
 -Biocon launches drug for breast cancer treatment
 -Biocon partners with Advaxis for novel cancer immunotherapy
 -Biocon launches flagship program in collaboration with KGI
 -Biocon Foundation bags WHO award
 -Biocon Strengthens its Presence in Mexico; Receives Approval for
 Insulin Glargine through its partner PiSA Farmaceutica
 -Biocon's CRO Arm Syngene Seeks Approval for IPO, Files DRHP
 -Biocon's Nationwide 'Winning with Diabetes' Campaign Raises
 Awareness on Disease Prevention & Management
 -NeoBiocon Partners with Novartis to offer Vildagliptin for Diabetics
 in UAE
 -Biocon launches new Hepatitis-C drug in India
 - Biocon is the Only Asian Company to be ranked in Top 20 Global
 Biotech Employers
 -Biocon Inaugurates World Class Devices Facility & Introduces Basalog
 -Biocon Academy Introduces First Of Its Kind Career Advancement
 Program in 'Quality Control Microbiology in Collaboration with BITS
 -Biocon receives Karnataka govt nod for Rs 1,060 cr plant
 -Biocon launches Insulin Glargine in Japan
 -  U.S. FDA Accepts Biologics License  Application (BLA) for Mylan
 and Biocon's  Proposed Biosimilar Trastuzumab
 -  Biocon Wins MYR 300 Million Contract for  Insulin from MoH,
 -   Biocon Foundation & Department of Medical,  Health & Family
 Welfare, Govt. of Karnataka  Collaborate to Set Up Smart eLAJ Clinics
 in  Karnataka
 - Kiran Mazumdar-Shaw Felicitated with 'AWSM Award for Excellence
 2017' by The Feinstein Institute for Medical Research, USA
 - Company Statement on Media Reports on USFDA 483s
 - Biocons Clarification post media reports on Biocon on the FDA list
 for not paying facility fee.
 Biocon has paid Facility Fee for its API facility to USFDA in Sep
 - Biocon Launches KRABEVA - Biosimilar Bevacizumab for Treating
 Several Types of Cancer in India
 - Biocon's Drug Product Facility Receives EIR with VAI status,
 Inspection Closed
 - Biocon Ltd receives positive CHMP opinion for SemgleeT
 - Biocon gets 6 observations from USFDA for Malaysia facility
 - Biocon Announces Exclusive Global Collaboration with Sandoz on
 Next-Generation Biosimilars
 - Mylan and Biocon Receive Approvals from the European Commission and
 TGA, Australia for Semglee Biosimilar Insulin Glargine
 - Biocon Ranked 7th on Top Global Pharma & Biotech Employers List
 -Biocon Ltd got Best Corporate University and Best Quality
 Improvement Award from CLO Tata Institute of Social Sciences (TISS),
 - It got Company with Great Managers and Great Manager Award from
 People Business Award
 - Best Training & Development Program by L&D World (L&D
 World-Transformance & Adobe)
 - Biocon wins Best Initiative in Employee Wellness at the 3rd
 Employee Engagement Leadership Awards
 - Biocon Biologics Expands its R&D Footprint Through Acquisition
 - Biocon and Mylan Launch First Insulin Glargine Biosimilar,
 Semglee, in Australia
 - Biocon Ltd Facility Completes Pre Approval U.S. FDA Inspection
 - Biocon and Mylan launch biosimilar of cancer drug Herceptin in US
 - Biocon ltd API Manufacturing Facility Completes Pre-Approval And
 GMP U.S. FDA Inspection
 - Biocon & Mylan Win Patent Litigation Asserted by Sanofi for Insulin
 Glargine Device Patent in U.S.
 - Biocon and Mylan Launch Fulphila Biosimilar Pegfilgrastim, in
 - Biocon Biologics and Voluntis Join Hands for Global Collaboration
 on Digital Therapeutics for Insulins
 - Biocon Ranked Among Top 5 Biotech Employers Globally
 - Biocon expands generic formulations portfolio with the launch of
 Tacrolimus capsules in the US
 - Biocon launches Everolimus tablets in the US market
 - Biocon enters into an out-licensing deal with Tabuk
 - Biocon Biologics First-Ever Interchangeable Biosimilar Insulin
 Glargine, Co-Developed with Commercial Partner Viatris, Preferred on
 Express Scripts Largest Formulary in US
 - Biocon Enters Prestigious Dow Jones Sustainability Emerging Markets
 - Biocon Ltd partners with Tabuk Pharmaceuticals to commercialise its
 speciality generic medicines in the Middle East